Table S4 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer

Key Points

• Refining treatment approaches improves outcomes in advanced hr+/her2- breast cancer patients.
• Real-world cohorts from three external centers highlight the effectiveness of precision treatment strategies.
• Subtyping-directed precision treatment shows promise over traditional one-size-fits-all therapy.
• These findings may lead to personalized care for those diagnosed with hr+/her2- breast cancer.